Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Fate Therapeutics (FATE) Stock Price & Analysis
1,112 Followers
FATE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.63 - $8.83
Previous Close$4.27
Volume1.00M
Average Volume (3M)2.43M
Market Cap
$486.06M
Enterprise Value$204.59M
Total Cash (Recent Filing)$383.54M
Total Debt (Recent Filing)$102.07M
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Jul 31, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding113,831,969
10 Day Avg. Volume2,554,227
30 Day Avg. Volume2,430,273
Standard Deviation0.23
R-Squared0.19
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.00
Price to Sales (P/S)6.74
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue31.58
Enterprise Value/Gross Profit3.22
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$6.55Price Target Upside53.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Fate Therapeutics News
PremiumCompany Announcements
Fate Therapeutics Announces CFO Change and Shareholder Approvals
PremiumCompany Announcements
Fate Therapeutics CFO Resigns, CEO to Assume RoleBulls Say, Bears Say
Bulls Say
Clinical ProgressFATE reported multiple clinical progress updates at ASGCT.
Innovative TechnologyFate’s NK-cell technology is opening new doors for cell therapy given its versatile and modular off-the-shelf products.
New Patient EnrollmentThe company has now dosed the first patient in FT819's Ph1 study for systemic lupus erythematosus (SLE).
Bears Say
Clinical TrialsFate's therapies may fail in the clinic.
Financial PerformanceFate will likely require additional cash and may face future litigation.
Program DevelopmentFate management has decided to wind down the program focused on developing FT576 in multiple myeloma.
---
Ownership Overview
24.99% Insiders
22.28% Mutual Funds
15.10% Other Institutional Investors
37.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $1.63 and its highest was $8.83 in the past 12 months.
What is Fate Therapeutics’s market cap?
Currently, no data Available
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Jul 31, 2024 which is in 10 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on May 09, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.472 by $0.002.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -$0.46.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 113,831,970 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.472. Following the earnings report the stock price went up 4.615%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Among the largest hedge funds holding Fate Therapeutics’s share is Deerfield Management Company, LP. It holds Fate Therapeutics’s shares valued at 16M.
---
Fate Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.55 (53.40% Upside)
$6.55 (53.40% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 5.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.17%
12-Months-Change
Fundamentals
Return on Equity
-42.07%
Trailing 12-Months
Asset Growth
-9.59%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
FATE Earnings Call
Q1 2024
0:00 / 0:00
---
FATE Stock 12 Month Forecast
Average Price Target
$6.55
▲(53.40% Upside)
Technical Analysis
Best Analysts Covering FATE
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
-1.10%
reiterated a buy rating 2 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of -1.10% per trade.
---